Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
September 23 2019 - 7:00AM
Scilex Holding Company (Scilex), a majority-owned subsidiary of
Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has
confidentially submitted a draft registration statement on Form S-1
to the U.S. Securities and Exchange Commission (the "SEC") relating
to its proposed initial public offering of its common stock. The
size and price range for the proposed offering have not yet been
determined. The initial public offering is expected to commence
after the completion of the SEC review process, subject to market
and other conditions.
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"), and shall not constitute an offer to sell, or
the solicitation of an offer to buy, any securities. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act.
Media and Investor Relations
Email: mediarelations@sorrentotherapeutics.com
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024